Search Results

You are looking at 91 - 100 of 2,919 items for :

  • Refine by Access: All x
Clear All
Full access

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

These entities stipulate 2 criteria to establish surrogacy: (1) good correlation between the surrogate endpoint and the final outcome (individual-level association) and (2) good correlation between the treatment effect on the surrogate endpoint and the

Full access

A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial

Hermioni L. Amonoo, Elizabeth Daskalakis, Emma D. Wolfe, Michelle Guo, Christopher M. Celano, Brian C. Healy, Corey S. Cutler, Joseph H. Antin, William F. Pirl, Elyse R. Park, Heather S.L. Jim, Stephanie J. Lee, Thomas W. LeBlanc, Areej El-Jawahri, and Jeff C. Huffman

impact outcomes, such as quality of life (QoL) and mortality, throughout the entire HSCT care and recovery continuum. 2 – 8 , 10 However, psychosocial interventions that reduce psychological distress while enhancing PPWB are lacking for the HSCT

Full access

Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response

Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst

, patients who still had residual disease in the breast did not have better outcomes compared with those who remained LN-positive. Cumulative incidence of LF, RF, and DF at 10 years by response to NAC is depicted in Table 2 , with corresponding cumulative

Full access

Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen

provide the convenience for self-medication at home; however, they increase the risks for nonadherence, drug interactions, and adverse drug events (ADEs), which may threaten therapeutic outcomes and patient safety. 2 Oral chemotherapy drugs are perceived

Full access

NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non–Small Cell Lung Cancer

Matthew A. Gubens and Marianne Davies

to have much poorer outcomes with single-agent immunotherapy. PD-L1 Expression ≥50% In KEYNOTE-024, pembrolizumab more than doubled median overall survival (mOS) compared with chemotherapy for patients with PD-L1 expression ≥50%, improving mOS to 30

Full access

Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes

Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park

, evaluating CIPN with a valid, reliable, and responsive outcome measure is critical in identifying early signs of nerve damage and effects of intervention aimed at preventing long-lasting or severe neurotoxicity. There are numerous approaches to assessing

Full access

Baseline Hemoglobin-A1c Impacts Clinical Outcomes in Patients With Pancreatic Cancer

Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman

outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma

Full access

Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy

Full access

Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma

Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini

data addressing management of this rare malignancy, we used the National Cancer Database (NCDB) to assess survival outcomes according to stage and treatment strategy in patients with anal adenocarcinoma. We focused our investigation on a comparison of

Full access

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

Jie-Hai Yu, Le-En Liao, Bin-Yi Xiao, Xuan Zhang, Ai-Wen Wu, Yong Cheng, Jing-Hua Tang, Wu Jiang, Ling-Heng Kong, Kai Han, Wei-Jian Mei, Zhi-Gang Hong, Wan-Jun Yang, Dan-Dan Li, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding

, suggesting the potential of PD-1 antibody as a curative-intent therapy. Subsequently, a larger cohort (n=19) from our team reinforced the exceptional short-term outcome of the WW strategy in patients with dMMR/MSI-H rectal cancer who experienced cCR after